Accord Healthcare, Inc. v. Helsinn Healthcare S.A. et al.

I'll research this case carefully. Let me start with the core docket and the patent.

Good foundation. Now let me dig into the petition grounds, the settlement, and the parallel litigation outcomes.

Now let me verify the district court outcome for Accord and the PGR's place in history.

Case Overview — Accord Healthcare, Inc. v. Helsinn Healthcare S.A., PGR2014-00010 (P.T.A.B.)

Parties and commercial context. Helsinn Healthcare S.A. is a privately held Swiss pharmaceutical company (Lugano-Pazzallo) that owns NDA No. 021372 for Aloxi®, the branded palonosetron hydrochloride intravenous injection indicated for chemotherapy-induced nausea and vomiting (CINV); Aloxi was marketed in the U.S. by Helsinn's distribution partner Eisai at the relevant time. Helsinn is a classic operating company, not an NPE — it develops and sells the drug and asserts Orange Book patents to protect it. Co-patent-owner and co-plaintiff Roche Palo Alto LLC (a Delaware entity based in South San Francisco) is a co-assignee of the '219 patent; its Rule 7.1 disclosure in the parallel Delaware case identified Roche Holdings, Roche Finance and Novartis Ltd as parents (D. Del. 13‑2101 corporate disclosure). The petitioner, Accord Healthcare, Inc. (Durham, N.C.), is a generic manufacturer and, per Helsinn's complaint, a wholly owned U.S. subsidiary and agent of India's Intas Pharmaceuticals Ltd. — which is why the caption's "et al." matters: the real dispute is Accord/Intas's ANDA No. 204615 for generic palonosetron HCl 0.25 mg/5 mL, bioequivalent to Aloxi (Complaint, D. Del. 13‑2101). Helsinn filed that Hatch-Waxman suit on December 27, 2013 — 24 days after the patent issued — against Accord and Intas in D. Del. (C.A. No. 13‑2101‑GMS, Chief Judge Gregory M. Sleet); Intas was voluntarily dismissed by stipulation in early 2014, and the case was later consolidated into C.A. No. 13‑688‑GMS with the Aurobindo/Ben Venue/Cipla actions (Stipulation, D.I. 56). The main Aloxi validity fight was elsewhere: Helsinn v. Teva, D.N.J. No. 11‑3962 (Judge Mary L. Cooper).

The patent and the challenge. Only one patent is at issue in the PGR: U.S. Patent No. 8,598,219 B2, "Liquid Pharmaceutical Formulations of Palonosetron" (issued Dec. 3, 2013; inventors incl. Giorgio Calderari; Orange Book expiry July 30, 2024 with pediatric exclusivity). In one line: a single-use 5 mL sterile, isotonic IV solution containing 0.25 mg palonosetron HCl (free-base basis), 0.005–1.0 mg/mL EDTA and 10–80 mg/mL mannitol, stable for 24 months at room temperature — i.e., the commercial 0.05 mg/mL Alox

I'll research this. Note up front: PGR2014-00010 is a PTAB post-grant review, not a district court infringement suit — but there is a parallel D.N.J. infringement action involving Accord and the '219 patent. Let me dig into both tracks.

Let me dig deeper into the PTAB record and the parallel district court case involving Accord.

Now let me pull the D. Del. docket involving Accord and the stipulation that removed the '219 claims.

I'll research the counsel of record for the petitioner/plaintiff in this matter. Note up front: PGR2014-00010 is a PTAB post-grant review, not a district court infringement suit, so the "plaintiff" side here is the petitioner, Accord Healthcare, Inc. Let me search the PTAB record and related litigations.

Good — I have the PTAB counsel names. Now let me verify identity, firm, and credentials for petitioner's counsel, and pull the petition signature block.

Let me pin down Michael Fink's firm and pull the petition's counsel designation page directly.

Scope correction first

PGR2014-00010 is not a patent infringement case — it is a PTAB post-grant review, so there is no "plaintiff," only a petitioner. The party aligned with "plaintiff" here is the petitioner, Accord Healthcare, Inc. The true infringement action (Helsinn Healthcare S.A. v. Accord Healthcare, Inc., D. Del. C.A. No. 13‑2101‑GMS) had Helsinn and Roche Palo Alto as plaintiffs and Accord as defendant — so I've addressed both sides below, since "plaintiff's counsel" is genuinely ambiguous on these facts.

One further correction to the record: the proceeding did not reach an institution decision on the merits. The parties filed a Joint Motion to Terminate (Paper 7, 2014‑11‑20) with a joint request to treat the settlement agreement as business confidential (Paper 8), and the Board entered a Judgment – Termination of the Proceeding under 37 C.F.R. §§ 42.72–42.73 (Paper 10, 2014‑11‑24), followed by a refund approval (Paper 12, 2014‑12‑15) (Docket Alarm docket for PGR2014‑00010). So "institution denied" is the aggregator's label; the file shows a settlement-driven termination before institution.

Petitioner's counsel — Accord Healthcare, Inc. (the "plaintiff" side)

Verification and caveats on this entry — read carefully:

• The name comes from PTAB case metadata listing "Petitioner Counsel: Michael Fink" (IPVerse PGR2014‑00010), which is consistent with the petition's own designation language ("Petitioner's designation of counsel: Lead counsel is Michael J…") visible in the petition text posted at patentdocs.typepad.com/files/303859.pdf.
• The firm attribution (Greenblum & Bernstein) is drawn from USPTO registration and professional-profile records for the sole Reg. No. 31,827 "Michael J. Fink," not from a signature block I was able to open in this proceeding. PTAB petitions from 2014 are in PTAB E2E/PRPS, which I could not render in full here. Treat firm as high-confidence but confirm against the petition's signature page (Paper 1) and any Power of Attorney before publishing.
• I found no backup counsel, no in-house Accord/Intas attorney, and no local counsel listed for the petitioner in any source. At PTAB no local counsel is required, so that absence is expected rather than a gap in the record. IPVerse lists only the single petitioner-side name.
• Notably, Accord's district court counsel in the Aloxi ANDA litigation (D. Del. 13‑2101) are a separate set of attorneys; I was not able to verify their names from a docket sheet in this session and will not guess at them.

Patent owner's counsel — Helsinn / Roche (the "defendant" side; also D. Del. plaintiffs)

Because the request may be aimed at the Helsinn side, and because Helsinn's litigation team is the one that shows up as plaintiffs' counsel in the parallel infringement suits, here is that roster, which is well documented:

Sources: Helsinn's combined § 282 notice/exhibit filings in the Aloxi litigations, e.g. PTAB petition exhibit with Helsinn's counsel block; D.N.J. complaint signature block; IPR2015‑01550 exhibit list signed by Dittmann, Reg. No. 51,188. Helsinn's local Delaware counsel in the 13‑2101/13‑688 consolidated actions did not surface in any source I could open and should not be assumed.

Bottom line

• Petitioner Accord's only identified counsel of record: Michael J. Fink, Greenblum & Bernstein, P.L.C. (Reston, VA), lead counsel — name well sourced, firm attribution from registration records and flagged for a signature-block confirmation.
• Patent owner Helsinn/Roche: Eric W. Dittmann (Paul Hastings LLP, New York), lead, with O'Malley, Wexler, Conca, Ji and Ni on the team — fully sourced.
• The Board's file is public (the settlement agreement itself is confidential under the joint request at Paper 8), so no counsel is hidden by sealing; the only real limitation is that PTAB E2E's 2014-era petition PDFs aren't fully retrievable through open web search.

Scope note — who the "defendant" is in this case

PGR2014-00010 is not an infringement action; it is a PTAB post‑grant review. The party occupying the defendant-side role is therefore the Patent Owner, styled in the caption as "Helsinn Healthcare S.A. and Roche Palo Alto LLC, Patent Owner." (The infringement case in which Accord was actually a defendant is the parallel D. Del. action, Helsinn v. Accord, C.A. No. 13‑2101‑GMS — see the caveat at the end.)

The authoritative source for counsel of record is the Board's Judgment – Termination of the Proceeding, Paper 10 (Nov. 24, 2014), which lists the appearance block verbatim:

"For Patent Owner: Eric W. Dittmann ericdittmann@paulhastings.com; Naveen Modi naveenmodi@paulhastings.com; Mark E. Waddell mwaddell@loeb.com; Thomas L. Irving tom.irving@finnegan.com"
(Paper 10, PGR2014-00010)

Patent Owner (defendant-side) counsel of record

In-house: No Helsinn or Roche in-house attorney appears of record in PGR2014‑00010. For context, Helsinn's corporate signatories on powers of attorney in the related palonosetron post-grant proceedings were Riccardo Braglia (Group CEO) and Matteo Missaglia (General Counsel), Helsinn Healthcare S.A. (Power of Attorney, IPR2015‑01554) — that filing is from a different proceeding, so it is context only, not a PGR2014‑00010 appearance.

Co-counsel structure: the case was staffed as a three-firm defense — Paul Hastings (PTAB trial), Loeb & Loeb (the Hatch‑Waxman/ANDA dispute and patent-owner strategy), and Finnegan — with Roche Palo Alto joining Helsinn as co-patent-owner without separate counsel of record shown.

Petitioner (Accord) side — for completeness

The same judgment lists Accord's counsel; useful because the "defendant" in the district court case, Accord, was the petitioner here:

• Michael J. Fink (Reg. No. 31,827), mfink@gbpatent.com — Greenblum & Bernstein, P.L.C., 1950 Roland Clarke Place, Reston, VA 20191 (703‑716‑1191). Partner; frequent PTAB lead counsel for petitioners and patent owners in pharma/mechanical cases.
• Paul A. Braier, Ph.D., pbraier@gbpatent.com — Greenblum & Bernstein, P.L.C., Reston, VA. Shareholder with a doctorate; backup counsel on Accord's petition.

(An aggregator summary (IP Verse) lists only "Petitioner Counsel: Michael Fink / Respondent Counsel: Eric Dittmann," which matches but understates the of-record teams above.)

Caveats and flags

1. Contradiction to flag on the record below. The docket entry is captioned by some databases as a "Final Decision," but Paper 10 is a termination judgment under 37 C.F.R. §§ 42.72–42.73, entered on the parties' joint motion to terminate (Paper 7) and settlement agreement (Ex. 2001) filed Nov. 20, 2014, while the patent owner's preliminary response was still not due. So the proceeding ended by settlement before any institution decision — consistent with the "institution denied / closed" status, and with Google Patents' "(Settlement)" tag; it was not a merits denial of institution.
2. If you meant the D. Del. infringement case (Helsinn Healthcare v. Accord Healthcare & Intas, C.A. No. 13‑2101‑GMS, filed Dec. 27, 2013), I was not able to verify that docket's defense-side appearances in this session — the searches surfaced the complaint and the later stipulation (D.I. 56) but not named Accord/Intas counsel. Those names should be pulled from the D. Del. docket sheet or the Rule 7.1/answer filings (Accord's PTAB counsel at Greenblum & Bernstein were PTO practitioners, not necessarily the D. Del. trial team). I am not filling that gap by inference.
3. Sourcing quality: the names, firms, e-mail addresses and Mark Waddell's registration number are taken directly from the Board's Paper 10 appearance block and a PTAB power of attorney listing for him; the biographical characterizations of Dittmann, Modi and Waddell come from firm bios/press coverage (including Loeb's Hatch‑Waxman practice announcements) and are descriptive rather than docket-verified for this specific matter.